Fail­ure in piv­otal PhI­II brain can­cer tri­al drags Is­rael's VBL Ther­a­peu­tics down

VBL Ther­a­peu­tics $VBLT is in cri­sis mode this morn­ing af­ter it an­nounced that its lead drug flunked a Phase III study in brain can­cer.

The tri­al, which com­pared a com­bo of VB-111 and Roche’s Avastin (be­va­cizum­ab) against Avastin alone among pa­tients with re­cur­rent glioblas­toma, failed the pri­ma­ry end­point of over­all sur­vival. That’s dispir­it­ing news for the Tel Aviv-based mi­cro-cap, which has tout­ed VB-111’s or­phan drug and fast track des­ig­na­tions every chance it gets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.